Arkolith/Insider Trading/TARS/Form 4

Neervannan Seshadri

Chief Operating OfficerTarsus Pharmaceuticals, Inc. (TARS) · full profile →Form 4 · filed Mar 17, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
1 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 15, 2026Option exercise(M)26K——97K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 15, 2026Option exercise(M)8K—$016K
Mar 15, 2026Option exercise(M)8K—$08K
Mar 15, 2026Option exercise(M)5K—$015K
Mar 15, 2026Option exercise(M)5K—$00

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001827584-26-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML